Entities / Company
Janssen Biotech.
Biotechnology company
- Reports this week
- 0
- Active events
- 0
- Connections
- 9
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
-
Protagonist Therapeutics co-discovered ICOTYDE with Johnson & Johnson and subsequently licensed the technology to Janssen Biotech.Well supported7 reports1 development inside
-
J&J and Janssen Biotech jointly won summary judgment in a Virginia court regarding J&J's acquisition, with FTC filing an amicus brief.Some support1 report
One to three months ago
-
Protagonist Therapeutics announced collaborations regarding rusfertide and licensed technology for the ICOTYDE™ product line.Some support3 reports
-
Legend Biotech and Janssen Biotech announced a partnership on January 22, 2026, to advance cell therapy treatments. The companies are headquartered in Somerset, New Jersey.Some support1 report
No events began in the chosen period. Widen it, or reset.
What's reaching Janssen Biotech
Events traced to Janssen Biotech, step by step, newest firstAround Janssen Biotech this week
News at the entities that move Janssen Biotech most-
Johnson & Johnson StructuralJohnson & Johnson joins the USMN initiative.Moves Janssen Biotech
-
company StructuralCompany Q783794 made an announcement originating from Lafox, Illinois, and is listed on Nasdaq.Moves Janssen Biotech
Connections
The 4 strongest of 9, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Johnson & Johnson Structural
Janssen Biotech operates as a licensed entity under Johnson & Johnson.
-
Protagonist Therapeutics (United States) Transactional
Protagonist Therapeutics licensed the drug Icotrokinra to Janssen Biotech following joint discovery and collaboration.
-
company Structural
Entity B supplies and licenses the product ICOTYDE to Janssen Biotech (Entity A).
-
Legend Biotech Operational
Legend Biotech and Janssen Biotech are partnering to advance cell therapy treatments.